Among the recently identified molecular DLBCL subtypes, genetic aberrations in NF-κB pathway components occurred predominantly in an ABC-DLBCL-related subset with MYD88L625P and CD79B aberrations (MCD [53]; cluster 5 [54]) and in a subset with BCL6 fusions, NOTCH2 mutations and TNFAIP3 lesions (BN2 [53]; cluster 1 [54]) that includes cases of ABC-, GCB- and unclassified DLBCL. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.